본문바로가기

Central nervous system

메인페이지로 이동
Business
Life Science
ETC
혈액순환개선제
Vimsk Inj.
Category
ETC
Indication(s)·Usage
  • Adjunctive therapy of partial seizure treatment with or without generalized seizure in epilepsy patients aged 16 and older

    Injections are administered to patients who are temporarily unable to administer oral administration.
Effective components
Lacosamide 10 mg/ml

Active ingredient(s) and Contents

  • Effective components

    • Lacosamide 10 mg/ml

  • Other

    • Sodium Chloride, Water for Injection, Hydrochloric Acid

Dosage and administration

  • Lacosamide therapy can be initiated with either oral or intravenous administration.
    The solution for infusion is infused over a period of 30 to 60 minutes twice daily. The solution for infusion can be administered intravenously without further dilution.

    Changing of route of administration (intravenous ↔ oral) can be done directly without titration. The total daily dose and twice daily administration shouldbe maintained.
    There is an experience with twice daily infusions for up to 5 days.

    • 1. Adults
      This drug should be administered twice daily. The recommended starting dose is 50 mg twice daily which should be increased to 100 mg twice daily after one week.
      Depending on response and tolerability, the maintenance dose can be increased at weekly intervals by 50 mg twice daily, up to a maximum recommended daily dose of 400 mg (200 mg twice daily).
      If the administration of this drug has to be discontinued, it is recommended this be done gradually (e.g., dose is gradually reduced by 200mg every week).

    • 2. Patients with renal impairment
      No dose adjustment is necessary in patients with mild to moderate renal impairment (CLcr>30mL/min). In patients with severe renal impairment (CLcr≤30mL/min) and in those with end-stage renal disease, the maximum dose is recommended 300 mg daily. As this drug is removed from plasma by hemodialysis, for all patients receiving hemodialysis are recommended to administer an additional dose of up to 50% of a single dose immediately after hemodialysis. Treatment of patients with end-stage renal disease should be made with caution as there is little clinical experience and accumulation of a metabolite (with no known pharmacological activity) In all patients with renal impairment, dose adjustment should be cautious.

    • 3. Patients with hepatic impairment
      The dose titration in patients with hepatic impairment should be cautious. In patients with mild or moderate hepatic impairment, the maximum dose is recommended 300 mg daily. In patients with severe hepatic impairment, the use of this drug is not recommended.

    • 4. Geriatric use
      No dose reduction is necessary in elderly patients. There is limited clinical data in elderly patients with epilepsy, but age associated decreased renal clearance with an increase in AUC levels should be considered in elderly patients. (see ‘Patients with renal impairment’ paragraph)

    • 5. Pediatric use
      As there are no data on safety and efficacy for pediatric patients under 16 years of age, this drug is not recommended for them.

Storage and handling

  • Hermetic container, keep at room temperature (1~30°C)
  • 310 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do
    463-400 Korea [13494]
  • Copyright(c) SK chemicals. All Rights Reserved.

Ethical Management

Site go
GO